Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Logistic regression analysis identified prior neurologic event (P = .046), nonelective surgery (P = .047), absence of coronary artery disease (P = .035), and preoperative angiotensin-converting enzyme inhibitor use (P = .029) to be associated with 30-day ipsilateral stroke risk, but contralateral ICA occlusion remained an independent predictor in that model (odds ratio, 2.29; P = .026).
|
31445827 |
2020 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
In regard to clinical studies, treatment with Angiotensin Converting Enzyme (ACE) inhibitors and AT1 receptor antagonists exerts preventive and therapeutic effects on stroke.
|
31849284 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Dual RAAS blockade with angiotensin-converting enzyme (ACE) inhibitor plus angiotensin receptor blockade (ARB) or ARB plus renin inhibition increases serious adverse events such as acute kidney injury and stroke.
|
30673886 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
We administered the National Adult Reading Test (NART, estimates premorbid or peak adult cognition) and the Revised Addenbrooke's Cognitive Examination (ACE-R; current cognition) at 1 and 12 months after stroke.
|
30875807 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75-0·95), hospitalisation for heart failure (0·83, 0·74-0·95), and stroke (0·83, 0·74-0·95) risk while on initial treatment.
|
31668726 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
History of stroke (odds ratio [OR]: 2·91, 95% confidence interval [CI]: 1·25-6·77) and use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (OR: 3·17, 95% CI: 1·28-7·84) were associated with rapid eGFR decline.
|
31168785 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
We recruited participants from inpatient and outpatient services with a lacunar or minor cortical ischaemic stroke (National Institutes of Health Stroke Scale score <8) and assessed current and premorbid cognitive functioning (Addenbrooke's Cognitive Examination-Revised (ACE-R), National Adult Reading Test (NART)), physical functioning (Timed Get Up and Go (TUG), 9-Hole Peg Test (9HPT)), dependency (modified Rankin Scale (mRS)), depression (Beck's Depression Inventory) in-person and remotely (Stroke Impact Scale).
|
30554134 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Angiotensin converting enzyme (ACE) gene has emerged as an important player in the pathogenesis of hypertension and consequently stroke.
|
31802381 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Association between Angiotensin-Converting Enzyme Inhibitors and Post-Stroke Aspiration Pneumonia.
|
31635965 |
2019 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) at stroke onset.
|
29549467 |
2018 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Prior stroke/TIA and/or PAD patients were less likely to receive evidence-based medical therapies (dual antiplatelet therapy: stroke/TIA= 88.6%, PAD= 86.6%, stroke/TIA+PAD= 85.7%, none= 92.2%, p<0.001; β-blockers: stroke/TIA= 77.1%, PAD= 72.1%, stroke/TIA+PAD= 71.9%, none= 80.8%, p<0.001; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: stroke/TIA= 86.3%, PAD= 83.6%, stroke/TIA+PAD= 83.2%, none= 87.1%, p=0.030) and to undergo percutaneous revascularization (stroke/TIA= 52.8%, PAD= 45.6%, stroke/TIA+PAD= 43.7%, none= 67.9%, p<0.001), despite more extensive coronary artery disease (three-vessel disease: stroke/TIA= 29.1%, PAD= 38.3%, stroke/TIA+PAD= 38.3%, none= 20.2%, p<0.001).
|
28627932 |
2018 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Amlodipine therapy was associated with 25% higher risk of heart failure (relative risk [RR]: 1.25, 95% confidence interval [CI], 1.05-1.49, P = .019) but 17% lower risk of stroke (RR: 0.83, [95% CI, 0.72-0.97], P = .009) without statistically significant effect on acute myocardial infarction (AMI) compared to major alternative antihypertensive therapy (MAAT), including β-blocker, diuretic, angiotensin-converting enzyme inhibitor, or angiotensin-receptor blocker.
|
29739234 |
2018 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We mainly observed a reduced risk of recurrent stroke in the subgroup of participants using an angiotensin-converting enzyme (ACE) inhibitor or a diuretic (I<sup>2</sup> statistic for subgroup differences 72.1%; P = 0.006).
|
30024023 |
2018 |
Cerebrovascular accident
|
0.600 |
AlteredExpression
|
group |
BEFREE |
These findings offer insight into ACE expression and activity in response to stroke, and further our understanding of ACE mechanisms.
|
29228591 |
2017 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Randomized, active controlled parallel group trials were included if they compared CCBs with α-blockers, β-blockers, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, or diuretics, had a follow-up of ≥6 months, and had assessments of blood pressure (BP) and CV events [all-cause death, CV death, major CV events (myocardial infarction, MI; congestive heart failure, CHF; stroke; and CV death), MI, stroke, or CHF] in patients with baseline systolic/diastolic BP ≥140/≥90 mm Hg with either concomitant previous stroke and/or CAD.
|
26588586 |
2017 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Angiotensin I converting enzyme (ACE) insertion/deletion (I/D) polymorphism is thought to affect renin-angiotensin system (RAS) activity and development of cardiovascular disease; significant associations between I/D polymorphism and atherosclerosis, stroke, nephropathy, and early mortality were already found.
|
28190172 |
2017 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and statins were of statistical significance for stroke risks.The majority of AF patients post-RFAs was of high stroke risk and received warfarin thromboprophylaxis in accordance with national guidelines.
|
29381974 |
2017 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Individuals harboring DD genotype of ACE I/D polymorphism are more predisposed to hemorrhagic stroke than ischemic stroke.
|
25015258 |
2015 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In pharmacogenetic analysis, the increased risk of stroke in subjects carrying G-6 was eliminated by concomitant treatment with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (P = .012 for interaction).
|
24732371 |
2014 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
ACE and ADD1 gene are known to be associated with vascular complications leading to stroke susceptibility.
|
21194526 |
2011 |
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
RGD |
The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-to head and in combination on stroke prevention in hypertensive rats and on potential neuroprotection in acute cerebral ischemia in normotensive rats.
|
21901125 |
2011 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The D allele of ACE I/D polymorphism may be a potential risk allele for stroke.
|
20300047 |
2010 |
Cerebrovascular accident
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We also performed functional studies by measuring serum ACE protein levels and enzymatic activity in 27 controls, 68 patients with IS at baseline and 35 patients with IS 24 h after onset of stroke symptoms.
|
20402757 |
2010 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
To study the influence of the APOE-epsilon4 allele and the ACE-I/D polymorphism on cognitive functioning after stroke.
|
20606435 |
2010 |
Cerebrovascular accident
|
0.600 |
GeneticVariation
|
group |
BEFREE |
This lack of association between stroke and ACE I/D polymorphism did not change in the presence of traditional risk factors (hypertension, diabetes mellitus, smoking, and dyslipidemia).
|
19596363 |
2009 |